
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical Inc. has raised its long-term net sales compound annual growth rate (CAGR) target to 6.5%-7.5%, reflecting continued strong growth expectations in its key segments. The company reported adjusted EBITDA of $23.9 million, a year-over-year increase of $4.3 million, demonstrating margin expansion and exceeding market consensus. Furthermore, significant growth was observed in both Spine Fixation and Bone Growth Therapies, with respective year-over-year increases of 12% and 9%, indicating robust demand and a strong market position in the orthopedic and spine solutions sector.
Bears say
Orthofix Medical Inc. has faced significant challenges following the discontinuation of its M6-C and M6-L artificial disc product lines, which were projected to generate $23.4 million in sales for 2024, highlighting a strategic shift away from certain product offerings in response to declining demand. The company’s long-term sales CAGR expectations have been adjusted downward, indicating a weaker growth trajectory as profitability remains pressured by ongoing competitive threats and integration risks associated with the merger with SeaSpine. Moreover, regulatory and reimbursement rate uncertainties further cloud the outlook, potentially hindering earnings and overall financial stability amid a complex and evolving healthcare landscape.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares